Table 2 Description of the intervention by study arm

From: A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation

Characteristics of the intervention

Placebo (n = 61)

MAG-EPA (n = 60)

p-value

Duration of intervention before RP (days) (mean ± Std)

52.0 ± 19.6

53.2 ± 37.4

0.82 §

Successful implementation of dosing regimen* (%)

78.5 †

79.4 ‡

0.83 ||

Adherence to intervention** (%) (mean ± Std)

87.5 ± 13.7

90.2 ± 14.8

0.30 §

RBC EPA at time of RP (% of total fatty acid) (mean ± Std)

0.79 ± 0.39

2.77 ± 0.79

<0.0001 §

Prostate tissue EPA at RP (% of total fatty acid) (mean ± Std)

0.26 ± 0.31

1.03 ± 0.46

<0.0001 §

  1. *Proportion of participants who underwent radical prostatectomy (RP) and took at least 80% of dose during the first 3 months. †n = 65, including 2 patients with unknown adherence: remaining pills not returned to the pharmacy (n = 1), stopped intervention before 3 months (n = 1). ‡n = 63, including 7 patients with unknown adherence: remaining pills not returned to the pharmacy (n = 3), stopped intervention before 3 months (n = 1), never adhered to intervention (n = 1), no explanation (n = 2). **Proportion of dose taken by participants who underwent RP (n = 128), excluding patients with unknown adherence (n = 2 placebo; n = 7 MAG-EPA). §p-value from independent samples t-test. ||p-value from Chi-square test. RBC red blood cells, MAG-EPA monoacylglyceride-conjugated eicosapentaenoic acid.
Back to article page